دورية أكاديمية
The road to tailored adjuvant chemotherapy for all four non-pancreatic periampullary cancers: An international multimethod cohort study.
| العنوان: | The road to tailored adjuvant chemotherapy for all four non-pancreatic periampullary cancers: An international multimethod cohort study. |
|---|---|
| المؤلفون: | Uijterwijk BA; Department of Surgery, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy. basuijterwijk@live.nl.; Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands. basuijterwijk@live.nl.; Cancer Center Amsterdam, Amsterdam, the Netherlands. basuijterwijk@live.nl., Lemmers DH; Department of Surgery, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.; Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands., Ghidini M; Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Wilmink JW; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands., Zaniboni A; Department of Medical Oncology, Fondazione Poliambulanza, Brescia, Italy., Fusai GK; Department of Surgery, Royal Free London NHS Foundation Trust, London, UK., Zerbi A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.; Department of Pancreatic Surgery, IRCCS Humanitas Research Hospital, Rozzano, Italy., Koerkamp BG; Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Luyer M; Catharina Hospital Eindhoven, Department of Surgery, Eindhoven, Netherlands., Ghorbani P; Division of Surgery, Department of Clinical Science, Intervention and Technology, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden., Salvia R; Department of Surgery, University Hospital of Verona, Verona, Italy., White S; Department of Surgery, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK., Ielpo B; Department of Surgery, Hospital del Mar, Barcelona, Spain., Goh BKP; Singapore General Hospital, Department of Hepatopancreatobiliary and Transplant Surgery, Duke-National University of Singapore, Singapore, Singapore., Boggi U; Department of Surgery, Pisa University Hospital, Pisa, Italy., Kazemier G; Cancer Center Amsterdam, Amsterdam, the Netherlands.; Amsterdam UMC, location VUmc, Amsterdam, the Netherlands., House MG; Department of Surgery, Indiana University School of Medicine, Indianapolis, IN, USA., Mavroeidis VK; Department of Academic Surgery, The Royal Marsden Hospital, London, UK.; Department of Hepatobiliary and Pancreatic Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Björnsson B; Department of Surgery in Linköping and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden., Mazzola M; Division of Oncologic and Mini-invasive General Surgery, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy., Serradilla M; Department of Surgery, Miguel Servet University Hospital, Zargosa, Spain., Korkolis D; Department of Surgery, Hellenic Anticancer Hospital 'Saint Savvas', Athens, Greece., Alseidi A; Department of Surgery, Virginia Mason, Seattle, WA, USA., Roberts KJ; Faculty of medicine, University of Birmingham, Birmingham, UK., Soonawalla Z; Department of Hepatobiliary and Pancreatic Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Pessaux P; Hepatobiliary and Pancreatic Surgical Unit, Nouvel Hôpital Civil (NHC), Strasbourg, France., Fisher WE; Department of Surgery, Baylor College of Medicine, Houston, USA., Koek S; Fiona Stanley Hospital, Department of Surgery, Perth, WA, Australia., Kent TS; Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA., Vladimirov M; Department of General Surgery, Paracelsus Medical University Nürnberg, 90419, Nürnberg, Germany., Bolm L; Department of Surgery, University Medical Center Schleswig-Holstein, campus Lübeck, Lübeck, Germany., Jamieson N; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK., Dalla Valle R; University Hospital of Parma, Department of Surgery, Parma, Italy., Kleeff J; Department of Surgery, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany., Mazzotta A; Department of Digestive, Oncologic and Metabolic Surgery, Institut Mutualiste Montsouris, Paris, France., Suarez Muñoz MA; Department of Surgery, University Hospital Virgen de la Victoria, Malaga, Spain., Cabús SS; Hospital de Sant Pau, Department of Surgery, Barcelona, Spain., Ball CG; Department of Surgery, University of Calgary, Calgary, AB, Canada., Berger AC; Department of Surgery, Jefferson Medical College, Philadelphia, USA., Ferarri C; Department of Surgery, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy., Besselink MG; Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.; Cancer Center Amsterdam, Amsterdam, the Netherlands., Hilal MA; Department of Surgery, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy. abuhilal9@gmail.com. |
| مؤلفون مشاركون: | International Study Group on non-pancreatic periampullary Cancer (ISGACA) |
| المصدر: | British journal of cancer [Br J Cancer] 2024 Jul; Vol. 131 (1), pp. 117-125. Date of Electronic Publication: 2024 May 28. |
| نوع المنشور: | Journal Article; Multicenter Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK Original Publication: London, Lewis. |
| مواضيع طبية MeSH: | Adenocarcinoma*/drug therapy , Adenocarcinoma*/pathology , Duodenal Neoplasms*/drug therapy , Duodenal Neoplasms*/pathology , Duodenal Neoplasms*/surgery, Humans ; Male ; Female ; Chemotherapy, Adjuvant ; Middle Aged ; Aged ; Cholangiocarcinoma/drug therapy ; Cholangiocarcinoma/pathology ; Cholangiocarcinoma/surgery ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Ampulla of Vater/pathology ; Pancreaticoduodenectomy ; Cohort Studies ; Common Bile Duct Neoplasms/drug therapy ; Common Bile Duct Neoplasms/surgery ; Common Bile Duct Neoplasms/pathology ; Common Bile Duct Neoplasms/mortality ; Bile Duct Neoplasms/drug therapy ; Bile Duct Neoplasms/pathology ; Bile Duct Neoplasms/surgery ; Retrospective Studies ; Capecitabine/therapeutic use ; Capecitabine/administration & dosage |
| مستخلص: | Background: Despite differences in tumour behaviour and characteristics between duodenal adenocarcinoma (DAC), the intestinal (AmpIT) and pancreatobiliary (AmpPB) subtype of ampullary adenocarcinoma and distal cholangiocarcinoma (dCCA), the effect of adjuvant chemotherapy (ACT) on these cancers, as well as the optimal ACT regimen, has not been comprehensively assessed. This study aims to assess the influence of tailored ACT on DAC, dCCA, AmpIT, and AmpPB. Patients and Methods: Patients after pancreatoduodenectomy for non-pancreatic periampullary adenocarcinoma were identified and collected from 36 tertiary centres between 2010 - 2021. Per non-pancreatic periampullary tumour type, the effect of adjuvant chemotherapy and the main relevant regimens of adjuvant chemotherapy were compared. The primary outcome was overall survival (OS). Results: The study included a total of 2866 patients with DAC (n = 330), AmpIT (n = 765), AmpPB (n = 819), and dCCA (n = 952). Among them, 1329 received ACT, and 1537 did not. ACT was associated with significant improvement in OS for AmpPB (P = 0.004) and dCCA (P < 0.001). Moreover, for patients with dCCA, capecitabine mono ACT provided the greatest OS benefit compared to gemcitabine (P = 0.004) and gemcitabine - cisplatin (P = 0.001). For patients with AmpPB, no superior ACT regime was found (P > 0.226). ACT was not associated with improved OS for DAC and AmpIT (P = 0.113 and P = 0.445, respectively). Discussion: Patients with resected AmpPB and dCCA appear to benefit from ACT. While the optimal ACT for AmpPB remains undetermined, it appears that dCCA shows the most favourable response to capecitabine monotherapy. Tailored adjuvant treatments are essential for enhancing prognosis across all four non-pancreatic periampullary adenocarcinomas. (© 2024. The Author(s), under exclusive licence to Springer Nature Limited.) |
| References: | Ann Surg. 2017 May;265(5):901-909. (PMID: 27232253) Am Soc Clin Oncol Educ Book. 2014;:112-5. (PMID: 24857067) Pancreatology. 2020 Apr;20(3):433-441. (PMID: 31987649) J Clin Oncol. 2019 Apr 20;37(12):1015-1027. (PMID: 30856044) HPB (Oxford). 2020 Mar;22(3):405-414. (PMID: 31494056) Anesthesiology. 1979 Aug;51(2):179. (PMID: 453623) Ann Surg. 2008 Mar;247(3):456-62. (PMID: 18376190) Surgery. 2016 Jun;159(6):1520-1527. (PMID: 26847803) J Clin Oncol. 2019 Mar 10;37(8):658-667. (PMID: 30707660) Ann Surg Oncol. 2015 Jul;22(7):2401-7. (PMID: 25503345) N Engl J Med. 2018 Dec 20;379(25):2395-2406. (PMID: 30575490) J Clin Oncol. 2009 Jun 1;27(16):2598-603. (PMID: 19164203) Am J Surg Pathol. 2012 Nov;36(11):1592-608. (PMID: 23026934) JAMA Oncol. 2022 Nov 1;8(11):1571-1578. (PMID: 36048453) Histopathology. 2020 Jan;76(2):182-188. (PMID: 31433515) Gastroenterology. 2000 Feb;118(2):379. (PMID: 10691372) Br J Surg. 2018 Feb;105(3):192-202. (PMID: 29405274) Expert Rev Gastroenterol Hepatol. 2021 May;15(5):483-485. (PMID: 33307876) J Natl Compr Canc Netw. 2023 Jul;21(7):753-782. (PMID: 37433437) J Gastrointest Surg. 2007 Mar;11(3):350-6. (PMID: 17458610) Pancreas. 2006 Apr;32(3):271-5. (PMID: 16628082) Ann Surg Oncol. 2018 Sep;25(9):2681-2692. (PMID: 29946997) Acta Chir Belg. 2023 Oct;123(5):502-508. (PMID: 35727126) N Engl J Med. 2004 Mar 18;350(12):1200-10. (PMID: 15028824) BMJ. 2009 Jun 29;338:b2393. (PMID: 19564179) Eur J Cancer. 2022 Mar;164:80-87. (PMID: 35182925) Surgery. 2007 May;141(5):610-8. (PMID: 17462460) Surgery. 2006 Nov;140(5):764-72. (PMID: 17084719) Ann Surg Oncol. 2010 Jun;17(6):1471-4. (PMID: 20180029) J Hepatobiliary Pancreat Surg. 2004;11(4):223-31. (PMID: 15368105) Saudi J Anaesth. 2019 Apr;13(Suppl 1):S31-S34. (PMID: 30930717) Surg Today. 2017 Mar;47(3):271-279. (PMID: 27236779) JAMA. 2012 Jul 11;308(2):147-56. (PMID: 22782416) Ann Surg Oncol. 2010 Apr;17(4):991-7. (PMID: 20108122) Jpn J Cancer Res. 1994 Feb;85(2):161-6. (PMID: 7511574) BMC Cancer. 2015 Jul 31;15:564. (PMID: 26228433) J Hepatobiliary Pancreat Sci. 2016 Sep;23(9):523-32. (PMID: 27524388) Ann Surg. 2020 Dec;272(6):1086-1093. (PMID: 30628913) N Engl J Med. 2010 Apr 8;362(14):1273-81. (PMID: 20375404) Surg Clin North Am. 2001 Jun;81(3):543-55. (PMID: 11459270) Br J Surg. 2020 Aug;107(9):1171-1182. (PMID: 32259295) Jpn J Clin Oncol. 2018 Apr 1;48(4):392-395. (PMID: 29462482) Br J Cancer. 2022 May;126(9):1280-1288. (PMID: 35039626) Cancer Manag Res. 2021 Mar 17;13:2567-2579. (PMID: 33762848) |
| المشرفين على المادة: | 6804DJ8Z9U (Capecitabine) |
| تواريخ الأحداث: | Date Created: 20240528 Date Completed: 20240708 Latest Revision: 20240802 |
| رمز التحديث: | 20240802 |
| مُعرف محوري في PubMed: | PMC11231293 |
| DOI: | 10.1038/s41416-024-02692-w |
| PMID: | 38806725 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 1532-1827 |
|---|---|
| DOI: | 10.1038/s41416-024-02692-w |